Chen X, Wang K, Liao Y, Zheng C, et al. Safety and efficacy of rechallenge with immune checkpoint inhibitors and anlotinib in advanced non-small cell lung cancer without targetable driver mutations: a retrospective analysis. BMC Cancer 2025;25:862.
PMID: 40355811